ArticleGene therapy2003
A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus.
Article in Gene therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 20 citations in OpenAlex.
- Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy.Journal for immunotherapy of cancer · 2021Article
- Virotherapy targeting cyclin E overexpression in tumors with adenovirus-enhanced cancer-selective promoter.Journal of molecular medicine (Berlin, Germany) · 2015Article
- Combination of autophagy inducer rapamycin and oncolytic adenovirus improves antitumor effect in cancer cells.Virology journal · 2013Article
- Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Oncolytic virotherapy for ovarian cancer.Oncolytic virotherapy · 2012Article
- Cancer screening by systemic administration of a gene delivery vector encoding tumor-selective secretable biomarker expression.PloS one · 2011Article
- Oncolytic viral therapy of malignant glioma.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2009Review
- Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.Gene therapy · 2006Article
- Tumor-specific intravenous gene delivery using oncolytic adenoviruses.Cancer gene therapy · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Confinement of transgene expression to target cells is highly desirable in gene therapy. Current strategies of transcriptional targeting to tumors usually rely on tissue-specific promoters to control gene expression. However, such promoters generally have much lower activity than the constitutive viral promoters. We have explored an alternative approach, using a strict-late viral promoter (UL38p) in the context of an oncolytic herpes simplex virus (HSV) for tumor-selective gene expression. As with many DNA viruses, the genomic transcription of HSV is a tightly regulated molecular cascade in which early and late phases of gene expression are separated by viral DNA replication. In particular, some of the late transcripts are categorized as strict-late, whose expression depends rigorously on the initiation of viral DNA replication. Our in vitro and in vivo characterization showed that in normal nondividing cells, where the oncolytic HSV has limited ability to replicate, the UL38p has minimal activity. However, in tumor or cycling cells where the virus can fully replicate, transgene expression from UL38p was almost as high as from the cytomegalovirus immediate-early promoter. These results suggest that delivery of therapeutic genes driven by UL38p through an oncolytic HSV may be an effective approach to gene therapy for malignant diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.